论文部分内容阅读
［目的］评价异环磷酰胺联合化疗治疗多种晚期恶性肿瘤的疗效及毒性。［方法］１９９５年１０月～１９９８年４月，５５例晚期非小细胞肺癌、恶性淋巴瘤和乳腺癌等肿瘤患者接受合异环磷酰胺为主的联合化疗，其中非小细胞肺癌２８例，恶性淋巴瘤８例，乳腺癌７例，其他肿瘤１２例。肺癌的化疗方案为ＭＩＣ和ＮＩＰ方案，恶性淋巴瘤为ＩＨＯＰ和ＭＩＶＥ方案，乳腺癌为ＩＡＦ和ＩＭＦ方案。［结果］５５例患者可评价疗效和毒性。总有效率５０．９％，ＣＲ８例，ＰＲ２０例。肺癌、恶性淋巴瘤和乳腺癌有效率分别为 ３９．３％，７５．０％和５７．１％。白细胞减少率为８９．１％，３～４级减少分别为３６．４％。血红蛋白减少和血小板减少分别为６９．１％和３８．２％，３级以上减少少见。非血液学毒性主要有恶心、呕吐４９．１％，脱发６５．５％，肝功能异常１６．４％。［结论］异环磷酸胺联合化疗作为一、二线治疗对多种晚期恶性肿瘤均有一定疗效。含异环磷酰胺的化疗方案及提高异环磷酰胺剂量强度治疗常见恶性肿瘤，值得临床深入研究。
[Objective] To evaluate the efficacy and toxicity of ifosfamide combined with chemotherapy in the treatment of multiple advanced malignant tumors. [Methods] From 1995 to April 1998, 55 patients with advanced non-small-cell lung cancer, malignant lymphoma, and breast cancer received combined cyclophosphamide-based chemotherapy, including 28 patients with non-small cell lung cancer. 8 cases of malignant lymphoma, 7 cases of breast cancer, 12 cases of other tumors. The chemotherapy regimens for lung cancer are the MIC and NIP regimens, the malignant lymphomas are the IHOP and MIVE regimens, and the breast cancers are the IAF and IMF regimens. [Results] 55 patients were evaluated for efficacy and toxicity. The total effective rate was 50.9%, CR8 cases, PR20 cases. The effective rates for lung cancer, malignant lymphoma, and breast cancer were 39.3%, 75.0%, and 57.1%, respectively. The leukopenia rate was 89.1%, and the 3 to 4 reductions were 36.4%. Reductions in hemoglobin and thrombocytopenia were 69.1% and 38.2%, respectively, and reductions above grade 3 were rare. The main non-hematologic toxicities were nausea, vomiting 49.1%, hair loss 65.5%, liver function abnormalities 16.4%. [Conclusion] Heterocyclic phosphate amine combined with chemotherapy as a first-line and second-line treatment has a certain effect on a variety of advanced malignant tumors. Ifosfamide-containing chemotherapy regimens and increased dose strength of ifosmamide for the treatment of common malignancies are worthy of clinical in-depth study.